COPLAND ROAD CAPITAL NEW

Research COPLAND ROAD CAPITAL NEW (A2P) on Bullrun: market cap EUR 699.39M, P/E 16.9, dividend yield 3.2%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 699.39M; P/E is 16.9; dividend yield is 3.2%.

Peer valuation comparison

Latest P/E is 16.94x versus a Healthcare sector median of 24.46x (30.7% below).

Latest dividend yield is 3.23% versus a Healthcare sector median of 2.11% (53.1% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025PLN 706.15MPLN 111.64MPLN 49.66M36.5%n/aPLN 166.24MPLN 32.37MPLN 258.34M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24EUR 699.39M16.93.1%2.55

Dividend history

Latest trailing dividend snapshot: annual dividend/share 2.55 EUR, yield 3.2%.

About COPLAND ROAD CAPITAL NEW

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics for oncology.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is COPLAND ROAD CAPITAL NEW's market cap?

COPLAND ROAD CAPITAL NEW's market capitalization is EUR 699.39M.

What is COPLAND ROAD CAPITAL NEW's P/E ratio?

COPLAND ROAD CAPITAL NEW's price-to-earnings (P/E) ratio is 16.9.

Does COPLAND ROAD CAPITAL NEW pay a dividend?

COPLAND ROAD CAPITAL NEW has a dividend yield of 3.2%.

What does COPLAND ROAD CAPITAL NEW do?

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics for oncology. In addition, it offers maintenance services for medical equipment, as well as acceptance and specialist tests. The company was founded in 2001 and is based in Warsaw, Poland.